COPD UNCOVERED

COPD:

Chronic Obstructive Pulmonary Disease

COPD Uncovered is driven by a multidisciplinary committee of international respiratory health experts, supported by global charity Education for Health and Novartis Pharma AG6

- 1. Fletcher MJ, et al. COPD Uncovered: An International survey on the impact of chronic obstructive pulmonary disease (COPD) on a working age population. BMC Public Health 2011:11:612
- 2. Murray, J.L et al (1996). The Global Burden of Disease, 2nd ed. United States of America: The Harvard School of Public Health. 361
- 3. Joshi M et al. Symptom burden in chronic obstructive pulmonary disease and cancer. Obstructive, occupational and environmental diseases, 2012:18(2).
- 4. Global Alliance Against Chronic Respiratory Diseases (GARD). Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Available at: http://www.who.int/gard/publications/GARD%20Book %202007.pdf. Last accessed 29 August 2013.
- 5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2013 http://www.goldcopd.org/guidelines-global-strategyfor-diagnosis-management.html. Last accessed 29 August 2013.
- 6. Quotation from COPD Uncovered Steering Committee. Document available at: http://www.educationforhealth.org/data/files/COPD report_sept11.pdf. Last accessed 29 August 2013.

THE IMPACT OF COPD ON A

WORKING-AGE POPULATION

COPD Uncovered

illustrates the urgent need for action

to combat this growing problem⁶

Need for early pharmacological and non-pharmacological interventions⁶, including:

Smoking cessation⁶

COPD is a major economic burden

for countries throughout the world^{1,5}

- Pulmonary rehabilitation⁶
- Appropriate treatments that may keep individuals in employment for longer⁶

Need for governments to address the COPD

epidemic by developing national strategies to strive for improved outcomes for patients and to minimize economic burden of COPD to societies⁶

COPD A progressive, life-threatening disease that makes it hard to breathe, with symptoms that have a detrimental impact on patients' function and quality of life (QoL)3

210 million people estimated to have COPD worldwide in 20004

COPD poses a major threat to society and is projected to be the

third leading cause of death by 2020²





HEART DISEASE

COPD

2020 -

is an ongoing research and educational initiative to investigate the economic, social, physical and emotional impact of COPD in people aged 45-67 years

More than half

of diagnosed COPD patients are under 65 years of age, at the prime of their lives and the peak of their earning power1

44%

of those employed worry about their future ability to earn an income as a consequence of their COPD1

COPD seriously affects the ability of **working-age** patients to contribute to society1

20%-40% of people with COPD

54-years-old

average age of retirement (which is 11 years early in

maintaining their previous lifestyle^{1,3,5}

More than a third

of patients report their total income has decreased as a consequence of their COPD1



retire prematurely due to their disease1

many countries)1

COPD symptoms, exacerbations and co-morbidities

place a major burden on patients and significantly reduce QoL^{3,5}

COPD can cause patients to

experience a **reduced QoL**,

difficulties undertaking daily

activities and problems

Novartis Pharma AG CH-4002 Basel, Switzerland

Need for improved

measures among health

authorities, payors and

healthcare professionals

to ensure COPD patients

are diagnosed early and

managed effectively to stay active and

productive in society6

Need for approaches that

working COPD patients to

continue with employment⁶

\$316,000 (\$200,000)

Estimated individual lifetime

prematurely1

income losses due to retiring

focus on improving

wellbeing and enable

awareness and

Print date: September 2013

Novartis item code: 159143

€38.6 billion

all respiratory diseases5

COPD direct healthcare costs in the

more than half of total spending on

European Union, representing

© 2013 - Novartis Pharma AG

on their lifestyle1